An interactive, moderated discussion among clinicians, health system executives, payers and health policy influencers discussing how to overcome the barriers to broader adoption of biosimilars in the United States.
Although biologic medicines are among the most innovative drugs to treat many life-threatening conditions, including cancer and autoimmune diseases, they represent only 2% of US prescriptions—but 43% of total pharmaceutical spending. When first-generation biosimilars were introduced in the United States, the hope was that they could moderate the rising cost of medicine. But this vision remains unrealized as biosimilars are vastly underutilized.
This special event explored the issues and opportunities that exist for wider adoption of biosimilars, with the goal of furthering affordable health care to give patients access to the treatments they need.
Tony Hagen, senior editor, The Center for Biosimilars®